WallStreetZenWallStreetZen

NASDAQ: BLTE
Belite Bio Inc Stock

$28.02+1.01 (+3.74%)
Updated Mar 27, 2023
BLTE Price
$28.02
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$8.80
52 Week High
$44.70
P/E
-27.74x
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.67M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.11
Operating Cash Flow
-$7M
Beta
-0.3
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

BLTE Overview

Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The company's pipeline of therapies is built on its RBP4 (Retinol Binding Protein 4) IP portfolio. Belite Bio is focused on meeting the unmet needs of patients suffering from blindness, liver disease, and diabetes. The company operates as a subsidiary of Lin Bioscience International Ltd. Belite Bio was founded in 2016 and is based in San Diego, CA.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BLTE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BLTE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BLTE is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
BLTE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more BLTE due diligence checks available for Premium users.

Be the first to know about important BLTE news, forecast changes, insider trades & much more!

BLTE News

Valuation

BLTE price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-27.74x
Industry
18.55x
Market
21.44x

BLTE's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
BLTE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$18.3M
Liabilities
$1.6M
Debt to equity
-0.11
BLTE's short-term assets ($17.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLTE's short-term assets ($17.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLTE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BLTE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
BLTE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BLTE vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ABCL$2.18B+3.27%13.54x1.77x
ABSI$159.84M+0.58%-1.99x0.55x
ACHV$91.98M+4.27%-1.28x11.08x
ABUS$497.47M+2.00%-6.65x3.64x
ACGN$8.34M+0.66%-0.36x0.40x

Belite Bio Stock FAQ

What is Belite Bio's quote symbol?

NASDAQ: BLTE) Belite Bio trades on the NASDAQ under the ticker symbol BLTE. Belite Bio stock quotes can also be displayed as NASDAQ: BLTE.

If you're new to stock investing, here's how to buy Belite Bio stock.

What is the 52 week high and low for Belite Bio (NASDAQ: BLTE)?

(NASDAQ: BLTE) Belite Bio's 52-week high was $44.70, and its 52-week low was $8.80. It is currently -37.32% from its 52-week high and 218.41% from its 52-week low.

How much is Belite Bio's stock price per share?

(NASDAQ: BLTE) Belite Bio stock price per share is $28.02 today (as of Mar 27, 2023).
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.